Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Gretchen Gayle

Nurse Practitioner, Psychiatric/Mental Health Meridian, ID Nurse Practitioner

NPI 1649757279 CMS profile 11039411

2321 E Gala St Ste 3, Meridian, ID 83642

Open in the dashboard

General payments

$3,780

184 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gretchen Gayle of Meridian, ID is reported in the CMS Open Payments database as having received $3,780 across 184 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,030 47
2024 General $690 32
2023 General $637 37
2022 General $458 21
2021 General $965 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gretchen Gayle
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Gretchen Gayle were reported at $1,030. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Gretchen Gayle Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $965 $166 $54–$482 $132
2022 $458 $195 $66–$559 $149
2023 $637 $233 $82–$673 $160
2024 $690 $236 $84–$688 $164
2025 $1,030 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Otsuka America Pharmaceutical, Inc. $711 46 payments
  2. Alkermes, Inc. $604 20 payments
  3. AbbVie, Inc. $334 21 payments
  4. Janssen Pharmaceuticals, Inc $320 12 payments
  5. Vanda Pharmaceuticals Inc. $285 8 payments
  6. ITI, Inc. $264 11 payments
  7. Teva Pharmaceuticals USA, Inc. $219 9 payments
  8. Corium, Inc. $203 11 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $146 9 payments
  10. Lundbeck LLC $128 7 payments
  11. Other $566 30 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,733 183 payments
  2. Education $47 1 payment
Products named General payments · program years 2021–2025
  1. LYBALVI Cns $444 14 payments
  2. ARISTADA Cns $354 16 payments
  3. ARISTADA Cns $354 16 payments
  4. LYBALVI Cns $311 7 payments
  5. INVEGA SUSTENNA $309 12 payments
  6. ARISTADA Cns $293 13 payments
  7. ARISTADA Cns $293 13 payments
  8. ABILIFY MAINTENA $292 20 payments
  9. FANAPT $285 8 payments
  10. VRAYLAR $267 17 payments
  11. Other $2,981 136 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

2,095

Median for Nurse Practitioner: 389

Drug cost

$135,043

Median for Nurse Practitioner: $21,885

Branded share of claims

24.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Caplyta Lumateperone Tosylate Brand 19 $30,100
Vraylar Cariprazine Hcl Brand 16 $21,488
Fanapt Iloperidone Brand 11 $18,415
Paliperidone Er Paliperidone Brand 33 $14,253
Lurasidone Hcl Generic 36 $10,074
Aripiprazole Generic 114 $6,353
Methylphenidate Er Methylphenidate Hcl Brand 30 $3,241
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 20 $2,862
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 63 $2,120
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 48 $2,053

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$31,865

Medicare's payments for the services billed

Medicare patients

185

Average age 54

Services billed

763

85 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 58%
Arthritis 34%
Diabetes 31%
COPD 19%
Ischemic heart disease 13%
Chronic kidney disease 13%
Atrial fibrillation 9%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FANAPT
  • Vanda Pharmaceuticals Inc. $191
$191 11 —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $127
$127 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $34
  • Lundbeck LLC $19
$54 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $50
$50 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

184 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record